Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

Deeper Dive: A Plethora of Prediction Models

Study Provides Insights That May Inform Prevention, Management of Mesothelioma

IASLC Releases Position Statement on Air Pollution on Earth Day

IASLC Responds to Call for Evidence

Researcher Reveals How Air Pollution May Cause Lung Cancer

Patient Comment on Mobocertinib for Exon 20

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation